AMRN Share Price

Open 3.19 Change Price %
High 3.20 1 Day 0.00 0.00
Low 3.14 1 Week 0.01 0.32
Close 3.17 1 Month -0.02 -0.63
Volume 944852 1 Year 1.27 66.84
52 Week High 3.65
52 Week Low 1.50
AMRN Important Levels
Resistance 2 3.23
Resistance 1 3.20
Pivot 3.17
Support 1 3.14
Support 2 3.11
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
SIRI 5.13 1.18%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
CYTR 0.83 36.07%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
CPSL 0.09 50.00%
LOCM 0.09 50.00%
RITT 0.03 50.00%
OPTT 2.74 49.73%
CYTR 0.83 36.07%
WRES 0.09 28.57%
BSDM 0.62 26.53%
ATRM 1.89 26.00%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Amarin Corporation PLC (NASDAQ: AMRN)

AMRN Technical Analysis 2.5
As on 24th Apr 2017 AMRN Share Price closed @ 3.17 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 2.93 & Strong Sell for SHORT-TERM with Stoploss of 3.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
AMRN Target for April
1st Target up-side 3.42
2nd Target up-side 3.57
3rd Target up-side 3.72
1st Target down-side 2.98
2nd Target down-side 2.83
3rd Target down-side 2.68
AMRN Other Details
Segment EQ
Market Capital 1595353216.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.amarincorp.com
AMRN Address
AMRN
2 Pembroke House
Upper Pembroke Street 28-32
Dublin, 2
Ireland
Phone: 353 1 669 9020
Interactive Technical Analysis Chart Amarin Corporation PLC ( AMRN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Amarin Corporation PLC
AMRN Business Profile
Amarin Corporation plc (Amarin), incorporated on March 1, 1989, is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial). The MARINE trial is conducted with omega-3 fatty acids in treating patients with very high triglycerides, is a Phase-III, multi-center, placebo-controlled, randomized, double-blind, 12-week study. Patients enrolled in the MARINE trial were given the option to be treated with AMR101 for a period of up to 40-weeks after their last dose in the pivotal trial. The ANCHOR trial is a multi-center, placebo-controlled, randomized, double-blind, 12-week pivotal study in patients with high triglycerides who were on optimized statin therapy. In April 2011, it reported top-line results from the ANCHOR trial. Prior to commencing the MARINE and ANCHOR trials, it conducted a pre-clinical program for AMR101, including toxicology and pharmacology studies. In addition to the MARINE and ANCHOR trials, it completed a 28-day pharmacokinetic study. It is also focusing development of other compounds based on its internal lipid science expertise.